CSF3 and Decreased total neutrophil count: In contrast to most chemotherapy drugs, health care professionals can administer BP-C1 in the patients’ own home, and BP-C1 is not associated with neutropenia, thereby avoiding the need for human recombinant G-CSF that is used to treat neutropenia after chemotherapy.27,28 As stated by Hurvitz et al chemotherapy-related adverse effects in MBC are associated with a substantial economic burden for society, which increases with the number of adverse effects reported.29 With none or fewer complications associated with BP-C1 treatment, the financial impact may be eliminated.